Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Sectors  >  Healthcare

News : Sectors

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors
11:28aMEDTRONIC : Launches Patient Engagement Program That Leverages Gamification to Help Motivate and Engage Patients Living with Diabetes
AQ
11:26aJOHNSON & JOHNSON : Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX Split Dosing Regimen
AQ
11:26aJOHNSON & JOHNSON : Announces Chris DelOrefice as Vice President of Investor Relations
AQ
11:25aINTELGENX TECHNOLOGIES : Reports Second Quarter 2018 Financial Results
AQ
11:11aSIHUAN PHARMACEUTICAL : Self-Developed Innovative Oncology Drug Pirotinib Commenced Phase II Clinical Trial in China
PU
11:06aGERRESHEIMER AT MEDTEC CHINA : order processing, industrial-scale production, and contract manufacturing from a single source
PU
10:51aINTEGRATED DIAGNOSTICS : Launch of radiology business in Egyptian market
PU
10:08aSTEMLINE THERAPEUTICS : Priority Review for Stemline's blood cancer therapy
AQ
10:08aBIOGEN : NICE draft guidance recommends against Spinraza for SMA
AQ
10:07aBIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
10:06aREGENERON PHARMACEUTICALS : FDA issues CRL for 12-week Eylea regimen
AQ
10:01aABCAM : Block listing Interim Review
PU
09:05aBIOTEST AG : Biotest increases revenues to EUR 200.7 million in the first half of 2018
EQ
09:04aAZURRX BIOPHARMA, INC. (NASDAQ : AZRX) Files An 8-K Regulation FD Disclosure
AQ
09:01aCATALENT : Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.
BU
12:10pAMPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
12:10pARTEMIS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
12:01pWELLCARE HEALTH PLANS : Announces Closing of $750 Million of Senior Notes
PR
12:01pSteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results
GL
11:56aILLUMINA : Notice of Intent to Sole Source Illumina brand NextSeq
AQ
11:49aXOMA : Reports Second Quarter 2018 Financial Results
AQ
11:49aMIRAGEN THERAPEUTICS : Reports Second Quarter 2018 Financial Results and Provides Corporate Update
AQ
11:49aVERTEX PHARMACEUTICALS : VRTX - FDA Approves ORKAMBI as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
AQ
11:49aMYOKARDIA : to Present at the 2018 Wedbush Pacgrow Healthcare Conference
AQ
11:49aMORPHOSYS : and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202
AQ
11:49aPACIRA PHARMACEUTICALS : to Present at the 2018 Wedbush Pacgrow Healthcare Conference
AQ
11:49aGENMAB : Announces Financial Results for the First Half of 2018
AQ
11:49aACELRX PHARMACEUTICALS : Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
AQ
11:49aHALOZYME THERAPEUTICS : Reports Second Quarter 2018 Results
AQ
11:48aANI PHARMACEUTICALS : Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
AQ
11:48aCORBUS PHARMACEUTICALS : Reports 2018 Second Quarter Financial Results and Provides Business Update
AQ
11:48aSUNESIS PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Recent Highlights
AQ
11:48aCATABASIS PHARMACEUTICALS : to Present at 2018 Wedbush PacGrow Healthcare Conference
AQ
11:48aGENMAB : Announces Submission of U.S. & EU Regulatory Applications Seeking Approval of DARZALEX Split Dosing Regimen
AQ
11:48aABATTIS BIOCEUTICALS : Announces share buy back program
AQ
11:48aSYNDAX PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
AQ
11:48aKERYX BIOPHARMACEUTICALS : Announces Second Quarter 2018 Financial Results
AQ
11:48aSYNERGY PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Business Update
AQ
11:48aNEOS THERAPEUTICS : Reports Second Quarter 2018 Financial Results
AQ
11:48aSUPERNUS PHARMACEUTICALS : Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
AQ
11:48aRA PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
AQ
11:48aMOTIF BIO : Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
AQ
11:48aKURA ONCOLOGY : to Present at 2018 Wedbush PacGrow Healthcare Conference
AQ
11:48aALBIREO PHARMA : to Present at Wedbush PacGrow Healthcare Conference
AQ
11:48aALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process
AQ
11:48aDepomed Announces Second-Quarter 2018 Financial Results
AQ
11:48aJOHNSON & JOHNSON : to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
AQ
11:48aCONCORDIA INTERNATIONAL CORP. : Announces Second Quarter 2018 Results
AQ
11:48aCATALYST PHARMACEUTICALS : Announces Second Quarter 2018 Financial Results and Provides Corporate Update
AQ
11:48aCHIMERIX : Announces Second Quarter 2018 Financial Results
AQ
11:48aELITE PHARMACEUTICALS : Glenmark Pharmaceuticals' partner Elite Pharmaceuticals receives US FDA approval for generic methadone hydrochloride tablets
AQ
11:48aCARA THERAPEUTICS : Reports Second Quarter 2018 Financial Results
AQ
11:48aMACROGENICS : Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results
AQ
11:48aAQUINOX PHARMACEUTICALS : Announces Second Quarter 2018 Financial Results
AQ
11:48aARROWHEAD PHARMACEUTICALS : Reports Fiscal 2018 Third Quarter Results
AQ
11:48aFATE THERAPEUTICS : to Present at the 2018 Wedbush PacGrow Healthcare Conference
AQ
11:48aGW PHARMACEUTICALS : Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress
AQ
11:48aCALITHERA BIOSCIENCES : Reports Second Quarter 2018 Financial Results and Recent Highlights
AQ
11:47aJOHNSON & JOHNSON : to Participate in Barclays Global Consumer Staples Conference
AQ
11:47aGLENMARK PHARMACEUTICALS : Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris for Patients with Seasonal Allergic Rhinitis
AQ
11:47aTG THERAPEUTICS : Provides Business Update and Reports Second Quarter 2018 Financial Results
AQ
11:47aPROGENICS PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock
AQ
11:46aROYAL PHILIPS : Philips and Targos collaborate to advance digital pathology education and enhance global training
PU
11:45aBTG : receives not-approvable letter from the US FDA for ELEVAIR
AQ
11:28aMEDTRONIC : Begins Pilot Study of Investigational Extravascular ICD System
AQ
Discover
12:27pPHIBRO ANIMAL HEALTH CORPORATION : to Participate in the Morgan Stanley Annual Global Healthcare Conference
AQ
12:26pFIBROGEN : FGEN) Shares Bought by Russell Investments Group Ltd.
AQ
12:26pCYTODYN : Appoints Michael A. Klump to Board of Directors
AQ
12:25pAgile Therapeutics Inc (AGRX) Holdings Cut by Russell Investments Group Ltd.
AQ
12:20pREFLECT SCIENTIFIC : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
1  2  3  4  5  6  7  8  9  10Next
Advertisement